Close Menu

NEW YORK ─ The Foundation for Innovative New Diagnostics and BIOASTER on Tuesday announced that they will work together on clinical studies to investigate antibody testing for COVID-19 and gain an understanding of how the immunological status of patients changes over time.

The clinical studies will aim to generate data on the possible association between the longevity of antibody response and the severity of COVID-19 over a period of nine to 10 months, using samples from patients seeking care at the Hospices Civils de Lyon and Centre Hospitalier Annecy Genevois in France.

To read the full story....

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.

Don't have a 360Dx or GenomeWeb account?
Register for Free.